Leukemia (2002) 16, 1200. DOI: 10.1038/sj/leu/2402493 TO THE EDITOR Vindesine (VDS), one of the vinca alkaloids, is widely used as an antineoplastic agent. Possible target sites are microtubules and tubulins in cancer cells. As the adverse effects of VDS, myelosuppression, alopecia and neurotoxicity are well-known. Neurotoxic effects are divided into four categories, peripheral neuropathy, autonomic neuropathy, encephalopathy and cranial nerve neuropathy. 1 In autonomic neuropathy, constipation and paralytic ileus are the most frequent manifestations. To our knowledge, there are no previous reports of mydriasis caused by VDS treatment.
A 22-year-old female demonstrated leukocytopenia and was given a diagnosis of acute promyelocytic leukemia (APL) by bone marrow aspiration in September 1997. She was treated with all-trans retinoic acid as an induction therapy 2 and complete remission (CR) was obtained. Three courses of consolidation therapies and two courses of intensification therapies were carried out, resulting in the maintenance of CR. The patient received a combination chemotherapy consisting of behenoyl cytarabine (170 mg/m 2 on days 1 to 5), etoposide (80 mg/m 2 on days 1, 3 and 5), and VDS (2 mg/m 2 on days 1 and 8) as the third intensification therapy. 2 On day 4 after VDS administration, the patient experienced photophobia and numbness of the mandible and tongue. Numbness decreased the next day, but photophobia persisted. On neurologic examinations, the pupils were round and equally dilated to 8 mm (Figure 1) , and reacted promptly to light. The ocular movements were normal in all directions and other cranial nerves were intact. There were no sensory abnormalities in the extremities and no motor dysfunction was detected. Tendon reflexes
Figure 1
Mydriasis after VDS administration. Mydriasis developed on day 4 after VDS administration. The diameter of the pupil equally dilated to 8 mm and light reflex persisted. Mydriasis disappeared by day 22 after discontinuing VDS administration. were symmetrical in the upper and lower extremities, and there were no pathological reflexes found. To clarify whether there was meningeal involvement of the APL, lumbar puncture and magnetic resonance imaging of the brain were carried out and findings were normal. Since it was the first time that VDS was given during the series of chemotherapies and numbness of the mandible and tongue caused by VDS administration 3 developed when the patient had mydriasis, it was speculated that mydriasis was also caused by VDS administration. Further administration of VDS on day 8 was not carried out. Mydriasis and photophobia gradually disappeared by day 22 without treatment.
In this case, the patient demonstrated mydriasis without disappearance of light and accommodation reflexes. Pupils become miotic by contraction of the papillary constrictor muscle in response to stimuli through the parasympathetic pathway. On the contrary, pupils become mydriatic by the contraction of the papillary dilator muscle in response to stimuli through sympathetic pathway. Mydriasis can be divided into two categories: paralytic mydriasis and spastic mydriasis. 4 Paralytic mydriasis occurs by the paralysis of the papillary constrictor muscle due to paralysis of the sympathetic pathway. While spastic mydriasis is caused by spasm of the papillary dilator muscle due to irritation of the sympathetic pathway, and light and accommodation reflexes persist during spastic mydriasis. 4 Spastic mydriasis is produced by irritation of the central or cervical sympathetic pathways or efferent nerves caused by spinal tumors, visceral diseases, cerebral tumors or administration of cocaine or adrenalin. 4 The administration of VDS induces irritation of the sympathetic nerve, resulting in spastic mydriasis in this case. Vinca alkaloids inhibit the outgrowth of neuritis and induce blockage of neural functions. 5 This is the first report that administration of VDS induced mydriasis caused by irritation of the sympathetic pathway.
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